Pill burden decreases and antiretroviral regimens simplify for many of the participants who start lenacapavir.

Researchers from the Institute of Human Virology (IHV) at the University of Maryland School of Medicine have discovered how a ...

Researchers from the Institute of Human Virology (IHV) at the University of Maryland School of Medicine have discovered how a ...

Despite the success of antiretroviral therapy (ART) in controlling HIV replication, a definitive cure remains elusive due to ...

Water Activation: One of the aspartic acid residues acts as a general base, activating a water molecule by abstracting a proton, while the other aspartic acid residue acts as a general acid, ...

Jefferies London Healthcare Conference 2025 November 17, 2025 10:00 AM ESTCompany ParticipantsLawrence Blatt - ...

Patients with and without HIV had similar 1- and 3-year survival outcomes following kidney transplantation, however, 5-year survival outcomes differed significantly.

ICIs are safe and effective for HIV-positive NSCLC patients, with no significant differences in survival outcomes compared to HIV-negative patients. Studies included in the review were mostly ...

Gilead Sciences has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. After comparing two phase 1 integrase strand transfer inhibitors, the Bay Area pharma ...

Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, 1 Baylor Plaza, Houston, Texas 77030, United States Verna and Marrs McLean Department of ...